Administration of Angiotensin-Converting Enzyme Inhibitors and β-Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?

BACKGROUND. Adjuvant trastuzumab therapy improves the outcome of patients with early breast cancer (EBC) and overexpression of human epidermal growth factor receptor 2 (HER2). However, it is potentially cardiotoxic. This study aims to evaluate the relationship between the use of angiotensin-converti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Oliva, Stefano, Cioffi, Giovanni, Frattini, Silvia, Simoncini, Edda Lucia, Faggiano, Pompilio, Boccardi, Lidia, Pulignano, Giovanni, Fioretti, Agnese Maria, Giotta, Francesco, Lestuzzi, Chiara, Maurea, Nicola, Sabatini, Silvia, Tarantini, Luigi
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2012
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3399646/
https://ncbi.nlm.nih.gov/pubmed/22673631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0445
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados